BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 745K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

17 articles for GA Doss

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
2-[(3aR,4R,5S,7aS)-5-{(1S)-1-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxyethoxy}-4-(2-methylphenyl)octahydro-2H-isoindol-2-yl]-1,3-oxazol-4(5H)-one: a potent human NK1 receptor antagonist with multiple clearance pathways.EBI
Merck Research Laboratories
Conformational studies of 3-amino-1-alkyl-cyclopentane carboxamide CCR2 antagonists leading to new spirocyclic antagonists.EBI
Merck Research Laboratories
Conformational analysis and receptor docking of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist.EBI
Merck Research Laboratories
2-Piperazinecarboxamides as potent and selective melanocortin subtype-4 receptor agonists.EBI
Merck Research Laboratories
Discovery of (2S)-N-[(1R)-2-[4-cyclohexyl-4-[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-4-methyl-2-piperazinecarboxamide (MB243), a potent and selective melanocortin subtype-4 receptor agonist.EBI
Merck Research Laboratories
Design of a novel pyrrolidine scaffold utilized in the discovery of potent and selective humanß3 adrenergic receptor agonists.EBI
Merck Research Laboratories
 
Diesters of zaragozic acid A: Synthesis and biological activityEBI
TBA
Potent, brain-penetrant, hydroisoindoline-based human neurokinin-1 receptor antagonists.EBI
Merck Research Laboratories
Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptin.EBI
Merck Research Laboratories
Highly constrained bicyclic VLA-4 antagonists.EBI
Merck Research Laboratories
Synthesis of functionalized 1,8-naphthyridinones and their evaluation as novel, orally active CB1 receptor inverse agonists.EBI
Merck Research Laboratories
Synthesis and activity of 4,5-diarylimidazoles as human CB1 receptor inverse agonists.EBI
Merck Research Laboratories
Potent Kv1.3 inhibitors from correolide-modification of the C18 position.EBI
Merck Research Laboratories
Diastereoselective synthesis and configuration-dependent activity of (3-substituted-cycloalkyl)glycine pyrrolidides and thiazolidides as dipeptidyl peptidase IV inhibitors.EBI
Merck Research Laboratories
Nonpeptide angiotensin II antagonists derived from 1H-pyrazole-5-carboxylates and 4-aryl-1H-imidazole-5-carboxylates.EBI
Merck Research Laboratories
Microbial transformation of L-696,474, a novel cytochalasin as an inhibitor of HIV-1 protease.EBI
Merck Research Laboratories
1,3,4-thiadiazole compounds and their use in treating cancerBDB
Astrazeneca